Watch for Ensifentrine (Ohtuvayre) for COPD

September 2024

You’ll get questions about ensifentrine (Ohtuvayre), a new nebulized med for COPD maintenance therapy in adults.

It’s the first dual phosphodiesterase 3 (PDE3) AND phosphodiesterase 4 (PDE4) inhibitor...that bronchodilates and reduces inflammation.

Oral roflumilast (Daliresp) for severe COPD only inhibits PDE4.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote